Figure 1

Amplicon targets for (A) atypical chemokine receptor 1 (ACKR1; n = 1), (B) the intergenic Dantu genetic blood variant SNP (n = 1), (C) haemoglobin subunit beta (HBB; n = 1), and (D) glucose-6-phosphate dehydrogenase (G6PD; n = 4). Four fragments for G6PD were designed to encompass five SNPs of clinical relevance, while one fragment designed for each of the three remaining regions of interest.